NEWSROOM

Medical

Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study

Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study

Dec 6, 2024

IRVINE, Calif., Dec. 04, 2024 - PRISM MediaWire - Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI™ assay. In a paper recently published in the journal Acta Neuropathologica Communications, DetermaCNI showed promise as a liquid biopsy method for diagnosing and profiling central nervous system tumors by measuring somatic copy number aberrations (SCNAs) in cerebrospinal fluid. For context, copy number...

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Nov 1, 2024

PITTSBURGH, PA, November 1, 2024 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (the “Company,” “our” or “us”), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that it intends to effect a 1-for-8 reverse stock split of its common stock effective as of 5:00 p.m. Eastern Time on November 7, 2024 upon the filing of a certificate of amendment to the Company’s certificate of...

NeuroOne® Medical Technologies to Present at the 2024 ThinkEquity Conference

NeuroOne® Medical Technologies to Present at the 2024 ThinkEquity Conference

Oct 24, 2024

EDEN PRAIRIE, Minn., October 24, 2024 - PRISM MediaWire - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate...

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

Oct 16, 2024

IRVINE, Calif., Oct. 16, 2024 - PRISM MediaWire - Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles. Oncocyte management will also be available for one-on-one meetings with investors. To schedule a one-on-one meeting, please contact Julie Silber at PCG Advisory (jsilber@pcgadvisory.com) or request a meeting via the LD Micro...

SS Innovations Conducts Interactive Meeting with the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) and Updates its Expected FDA Approval Timeline

SS Innovations Conducts Interactive Meeting with the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) and Updates its Expected FDA Approval Timeline

Sep 11, 2024

Fort Lauderdale, FL., September 11, 2024 - PRISM MediaWire - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery affordable and accessible to a global population, today issued an update on its progress and timeline in obtaining U.S. Food and Drug Administration (“FDA”) approvals to market the SSi Mantra Surgical Robotic System (“SSi Mantra”) in the United...

Halberd Corp. Issues Letter to Shareholders

Halberd Corp. Issues Letter to Shareholders

Aug 26, 2024

JACKSON CENTER, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB) today issued the following letter to its shareholders: Halberd Corp. - Taking a Moment to Recenter Our Technical Progress Introducing Tri-ax™ TBI Nasal Spray Treatment- the DoD selected our MSU-led pre-proposal, inviting us to submit a full application/proposal This is the first of a series of three significant Press Releases we plan to issue shortly. Many of our investors have been voicing...

ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility

ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility

Aug 26, 2024

Successful Conversion Eliminates Over $4 Million in Long-Term Debt New York, NY, August 26, 2024 - ANEW MEDICAL, INC. (NASDAQ: WENA), a leading U.S. biotechnology company pioneering cell and gene-based treatments for aging and age-related diseases, announces the successful conversion of its convertible promissory notes by investors. This strategic move significantly strengthens ANEW’s balance sheet by eliminating over $4 million in long-term debt. The elimination of over $4 million in...

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

Aug 22, 2024

Affecting about 6 million Americans, OLP is a chronic inflammatory disease affecting the mucous membranes of the mouth No FDA-approved therapy currently exists for OLP Patient registry and OLP study information is now available Pittsburgh, PA, August 22, 2024 – Lipella Pharmaceuticals, Inc. (NASDAQ: LIPO) has launched an Oral Lichen Planus (OLP) Patient Registry. This online platform is designed to enhance research and drive the development of new treatments for OLP, a chronic inflammatory...

Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte’s VitaGraft Study

Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte’s VitaGraft Study

Jun 3, 2024

New York, June 3, 2024—Oncocyte’s (Nasdaq: OCX) VitaGraft Kidney™ diagnostic test for transplant monitoring has shown promising results in a Phase 2 clinical trial, published in the prestigious New England Journal of Medicine. The trial evaluated the test's effectiveness in monitoring graft health in patients with antibody-mediated rejection (AMR), a leading cause of kidney transplant failure. The study's positive outcomes highlight new clinical uses for VitaGraft Kidney, including therapeutic...

SS Innovations’ SSi Mantra Surgical Robotic System Used to Perform 100 Cardiac Surgeries, Signaling Market Expansion

SS Innovations’ SSi Mantra Surgical Robotic System Used to Perform 100 Cardiac Surgeries, Signaling Market Expansion

May 21, 2024

The SSi Mantra has surpassed the 100 surgery milestone for robotic cardiac surgery SS Innovations maintains the world's only comprehensive robotic cardiac surgery program SSi Mantra used in more than 1000 procedures globally Company anticipates FDA approval in early 2025 FORT LAUDERDALE, FL, May 21, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making world class robotic surgery...

SS Innovations Achieves Pediatric Milestone with First Infant Pyeloplasty Using SSi Mantra Surgical Robotic System

SS Innovations Achieves Pediatric Milestone with First Infant Pyeloplasty Using SSi Mantra Surgical Robotic System

Apr 29, 2024

Company’s flagship SSi Mantra surgical device has now been used in more than 1000 procedures FORT LAUDERDALE, FL, April 29, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the successful performance of the first pyeloplasty procedure performed on an infant utilizing its flagship SSi Mantra...

SS Innovations Achieves Pediatric Milestone with First Infant Pyeloplasty Using SSi Mantra Surgical Robotic System

SS Innovations International Announces Q1 2024 Company Updates

Apr 22, 2024

Significant milestones achieved for SSi Mantra Made-in-India surgical robotic system FORT LAUDERDALE, FL, April 22, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making world class robotic surgery affordable and accessible to a global population, today announced its Q1 2024 Company updates. As of March 31, 2024, SS Innovations has completed a total of 32 successful installations of...

SS Innovations Achieves Pediatric Milestone with First Infant Pyeloplasty Using SSi Mantra Surgical Robotic System

SS Innovations’ Flagship SSi Mantra Surgical Robotic Device Successfully Completes Telesurgery Procedures

Apr 10, 2024

First-ever telesurgery using SSi Mantra performed on an animal in India FORT LAUDERDALE, FL, April 10, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making world class robotic surgery affordable and accessible to a global population, today announced that its SSi Mantra Surgical Robotic System has successfully completed its first-ever telesurgery procedures on an animal in India....

SS Innovations Achieves Pediatric Milestone with First Infant Pyeloplasty Using SSi Mantra Surgical Robotic System

SS Innovations’ SSi Mantra Surgical Robotic System used to perform Mitral Valve Replacement

Mar 12, 2024

The first Mitral Valve Replacement using the Made in India SSi Mantra Surgical Robotic System was successfully performed at the Narayana Institute of Cardiac Sciences in Bengaluru, India FORT LAUDERDALE, FL, March 12, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII) ), a developer of innovative surgical robotic technologies dedicated to making world class robotic surgery affordable and accessible to a global population, today announced that surgeons...

SS Innovations Achieves Pediatric Milestone with First Infant Pyeloplasty Using SSi Mantra Surgical Robotic System

SS Innovations Demonstrates Groundbreaking Telesurgery Platform at Company’s First Multi-Specialty Robotic Surgical Conference

Feb 1, 2024

Remote coronary artery suturing performed on animal model via SS Innovations’ telesurgery platform SMRSC 2024 welcomed global medical experts and innovators to explore the future of robotic surgery FORT LAUDERDALE, FL, February 01, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII) ), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, conducted a groundbreaking live...

SS Innovations Achieves Pediatric Milestone with First Infant Pyeloplasty Using SSi Mantra Surgical Robotic System

SS Innovations Announces Filing of Pre-Submission Application to the Center for Devices and Radiological Health (CDRH) of the United States Food and Drug Administration

Jan 26, 2024

FORT LAUDERDALE, FL, January 26, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that it has filed a pre-submission application with the U.S. Food and Drug Administration (FDA) requesting feedback on its SSi MantraTM Surgical Robotic System. SS Innovations received acknowledgement of this pre...

SS Innovations Achieves Pediatric Milestone with First Infant Pyeloplasty Using SSi Mantra Surgical Robotic System

SS Innovations Partners with India’s Leading Medical Equipment Supplier, Medikabazaar

Jan 25, 2024

Collaboration to facilitate sales of the SSi Mantra Surgical Robotic System to hospitals and medical facilities across India FORT LAUDERDALE, FL, January 25, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced it has entered into a partnership with India’s leading medical equipment supplier,...

SS Innovations Achieves Pediatric Milestone with First Infant Pyeloplasty Using SSi Mantra Surgical Robotic System

SS Innovations Launches Groundbreaking Inaugural Multi-Specialty Robotic Surgical Conference

Jan 22, 2024

SMRSC 2024 brings global medical experts and technological innovators together to explore the future of robotic surgery 13 Live, broadcasted surgeries were performed by distinguished multi-specialty surgeons, using the SSi Mantra Surgical Robotic System Distinguished guests included the Honorable Governor of Haryana, Mr. Bandaru Dattatreya FORT LAUDERDALE, FL, January 22, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII), a developer of innovative...

SS Innovations Achieves Pediatric Milestone with First Infant Pyeloplasty Using SSi Mantra Surgical Robotic System

SS Innovations Achieves Significant Milestones in 2023

Jan 8, 2024

Company’s award winning SSi Mantra surgical robotic system has completed over 550 surgeries and is clinically validated to perform more than 40 different types of surgical procedures Company Builds Strong Foundation for Future Growth FORT LAUDERDALE, FL, January 8, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population,...

SS Innovations Achieves Pediatric Milestone with First Infant Pyeloplasty Using SSi Mantra Surgical Robotic System

SS Innovations Announces Strategic Partnership with Surgical Lab for Distribution in Africa

Dec 26, 2023

Pan African Medical Device Distributor Surgical Lab to place the SSi Mantra Surgical Robotic System in Healthcare Facilities across the African Continent Surgical Lab has Begun Registration of SSi Mantra in 27 African countries FORT LAUDERDALE, FL, December 26, 2023 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC:SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population,...

Argentum 47 is Revolutionizing Business Energy Claims in the UK with Arg AI

Argentum 47 is Revolutionizing Business Energy Claims in the UK with Arg AI

Dec 5, 2023

WINDSOR, UK, December 5, 2023 – Argentum 47, Inc. (OTC PINK: ARGQ), a leading provider of AI-powered digital marketing solutions including branding, advertising, and lead generation, is excited to announce its Revolutionizing Business Energy Claims initiative in the UK with AI Marketing Tools. Argentum 47, Inc., a leading player in the technology and artificial intelligence sector, is setting out to transform the landscape of business energy claims in the United Kingdom by leveraging...

Argentum 47, Inc. Embraces the Future by Advancing SaaS Build, Moving to Prestigious New Address, and Pioneering AI Lead Generation for UK Government’s Eco4 Scheme

Argentum 47, Inc. Embraces the Future by Advancing SaaS Build, Moving to Prestigious New Address, and Pioneering AI Lead Generation for UK Government’s Eco4 Scheme

Nov 21, 2023

WINDSOR, UK, November 21, 2023 – Argentum 47, Inc. (OTC PINK: ARGQ), a leading provider of AI-powered digital marketing solutions including branding, advertising, and lead generation, is excited to announce three major developments that mark a significant step forward in its commitment to providing top-tier services to the Company’s valued clients, supporting sustainability, and driving innovation. These developments include taking our Software-as-a-Service (“SaaS”) platform to new heights,...

Argentum 47, Inc. Issues Q3 2023 Letter to Shareholders

Argentum 47, Inc. Issues Q3 2023 Letter to Shareholders

Nov 2, 2023

Operational and Revenue Ramp Underway, Expected to Accelerate throughout 2024 WINDSOR, BERKSHIRE, UK, November 2, 2023 – Argentum 47, Inc. (OTC PINK: ARGQ), a leading provider of AI-powered digital marketing solutions including branding, advertising, and lead generation, today issued the following letter to shareholders from its Chief Executive Officer, Robert Stephenson. Dear ARGQ Shareholders The first half of 2023 reflects the business traction we have achieved after years of hard work...

Argentum 47, Inc. Moves into Online Cloud Business with New SaaS Module

Argentum 47, Inc. Moves into Online Cloud Business with New SaaS Module

Oct 24, 2023

WINDSOR, BERKSHIRE, UK, October 24, 2023 – Argentum 47, Inc. (OTC PINK: ARGQ), a leading provider of AI-powered digital marketing solutions including branding, advertising, and lead generation, today announced that it has developed the Company’s proprietary AI Technology and platforms into a SaaS (Software-as-a-Service) model. Argentum 47 unifies all aspects of Marketing under one roof in order to enhance efficiency and coherence in marketing strategies. The ARG-AI module is designed to...

Argentum 47 Inc. Ventures into the European Medical Cannabis Industry to Capitalize on the Growing Market

Oct 19, 2023

WINDSOR, BERKSHIRE, United Kingdom, October 19, 2023 – Argentum 47, Inc. ("Argentum" or the "Company")(www.argq.io) (OTC PINK: ARGQ), a leading provider of AI-powered digital marketing solutions including branding, advertising, and lead generation, announced today that it has entered into talks with a European medical cannabis company that is fully integrated with strategic assets along the entire value chain including cultivation, processing, and distribution of dry flower and oil...